Glatiramer acetate - Teva Pharmaceuticals

Drug Profile

Glatiramer acetate - Teva Pharmaceuticals

Alternative Names: COP-1; Copaxone; Copolymer-1

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Lundbeck A/S; Proneuron Biotechnologies; Takeda; Teva Neuroscience; Teva Pharmaceutical Industries
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Amyotrophic lateral sclerosis; Glaucoma; Huntington's disease; Neurological disorders

Most Recent Events

  • 26 Oct 2017 Teva Pharmaceuticals files patent infringement action against Mylan in Ireland
  • 26 Oct 2017 The United Kingdom's High Court of Justice dismisses claims filed against Mylan by Teva Pharmaceuticals for infringement of Teva's patent related to glatimer acetate 40 mg/mL in the UK
  • 05 Oct 2017 Synthon receives approval for glatiramer acetate injection, the first generic equivalent to Copaxone® injection (40 mg/mL) in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top